ADMA Biologics Inc vs iShares Bitcoin Trust — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while iShares Bitcoin Trust trades at $36.08. The key difference: ADMA Biologics Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| ADMA | IBIT | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Crypto-linked |
52-Week High | $20.38 | $71.29 |
52-Week Low | $7.60 | $33.29 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
IBIT trades at $36.24, showing minimal daily movement with a 0.01% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators remain neutral. The stock faces resistance at $37 and finds support at $36. Recent news highlights institutional interest in crypto ETFs, with BlackRock's digital assets head noting 'overwhelming demand' (Bloomberg, August 10, 2026).
The outlook remains cautious due to bearish technical signals and Bitcoin's 50% decline from 2025 peaks. Long-term potential exists via institutional adoption, but near-term risks include crypto market volatility and selective ETF inflows. Investors should weigh technical weakness against BlackRock's growing ETF footprint.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →